Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.

Fiorentino M, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, Pinto C.

Oncologist. 2014 Apr;19(4):430. doi: 10.1634/theoncologist.2013-0346. Epub 2014 Mar 20. No abstract available.

2.

[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].

Duan JC, An TT, Wu MN, Yang L, Bai H, Wang ZJ, Wang YY, Zhuo ML, Zhao J, Wang SH, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2012 May;35(5):323-8. Chinese.

PMID:
22883988
3.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.

N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.

4.

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF.

Clin Cancer Res. 2004 Dec 15;10(24):8195-203.

5.

Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.

Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M, Tanimoto M, Kiura K.

Lung Cancer. 2013 Sep;81(3):435-9. doi: 10.1016/j.lungcan.2013.05.021. Epub 2013 Jul 1.

PMID:
23809059
6.

EGFR mutations in squamous cell lung cancer in never-smokers.

Baik CS, Pritchard CC, Eaton KD, Chow LQ.

J Thorac Oncol. 2013 Jan;8(1):e6-7. doi: 10.1097/JTO.0b013e3182762d49. No abstract available.

7.

[Gefitinib-induced perforating dermatosis].

Fernández-Guarino M, Aldanondo I, González-García C, Garrido P, Marquet A, Pérez-García B, Jaén P.

Actas Dermosifiliogr. 2006 Apr;97(3):208-11. Spanish.

PMID:
16796971
8.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
9.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

10.

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.

Br J Cancer. 2006 Nov 20;95(10):1390-5. Epub 2006 Oct 24.

11.

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ.

Lung Cancer. 2006 Nov;54(2):201-7. Epub 2006 Sep 7.

PMID:
16956694
12.

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

Shih JY, Gow CH, Yang PC.

N Engl J Med. 2005 Jul 14;353(2):207-8. No abstract available.

13.

EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.

Iyevleva AG, Novik AV, Moiseyenko VM, Imyanitov EN.

Urol Oncol. 2009 Sep-Oct;27(5):548-50. doi: 10.1016/j.urolonc.2008.03.022. Epub 2008 Jul 14.

PMID:
18625569
14.

Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.

Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH.

J Korean Med Sci. 2009 Jun;24(3):448-52. doi: 10.3346/jkms.2009.24.3.448. Epub 2009 Jun 12.

15.

Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.

Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC.

Oncologist. 2008 Dec;13(12):1276-84. doi: 10.1634/theoncologist.2008-0093. Epub 2008 Dec 5.

16.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
17.

KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.

Gottschling S, Penzel R, Pelz T, Herpel E, Schnabel PA, Dyckhoff G, Thomas M, Kuhnt T.

J Clin Oncol. 2011 Jul 20;29(21):e616-9. doi: 10.1200/JCO.2011.34.5892. Epub 2011 May 9. Review. No abstract available.

PMID:
21555681
18.

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N.

Jpn J Clin Oncol. 2013 Jun;43(6):664-8. doi: 10.1093/jjco/hyt049. Epub 2013 Apr 12.

PMID:
23585689
19.

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.

Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ.

Clin Cancer Res. 2005 Jun 15;11(12):4289-94.

20.

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.

Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S.

Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17.

PMID:
20401612

Supplemental Content

Support Center